Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: NOVARTIS PHARMACEUTICALS UK LIMITED, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
Lamisil Tablets 250mg.
| Pharmaceutical Form |
|---|
|
Tablets for oral administration. LAMISIL Tablets 250mg: Whitish to yellow tinged white, circular, biconvex tablets, scored on one side and coded LAMISIL 250 on the other. |
Each tablet contains 281.25mg terbinafine hydrochloride, equivalent to 250mg terbinafine.
| Active Ingredient | Description | |
|---|---|---|
| Terbinafine |
Terbinafine is an allylamine which has a broad spectrum of antifungal activity. Terbinafine acts by inhibition of squalene epoxidase in the fungal cell membrane. At low concentrations terbinafine is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity versus yeasts is fungicidal or fungistatic depending on the species. |
| List of Excipients |
|---|
|
Magnesium stearate |
PVC blister pack containing 7, 14 or 28 tablets.
NOVARTIS PHARMACEUTICALS UK LIMITED, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR
PL 0101/0304
01 November 2001
| Drug | Countries | |
|---|---|---|
| LAMISIL | Austria, Australia, Brazil, Canada, Cyprus, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
